Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Some newer azoles are still in development, but most only target candidiasis. Many years ago we saw development of nikkomycin (Nik Z), a drug mainly for coccidioidomycosis (Valley Fever). It has no appreciable activity against candida or aspergillus. Then there Continue reading The Antifungal Landscape – 1
David Larwood, CEO of VFS, summed it up at the Cocci FDA workshop in 2020: “When the market opportunity is limited, finding investment becomes the key issue”. He mentioned other problems as well: “Very low patient numbers for disseminated disease, Continue reading Draft FDA Guidance for COCCIDIOIDOMYCOSIS
It is time for a new look at the field of QIDP drugs. Today we are providing an updated searchable database which now has 57 entries. (Status: 10/18/16) Despite best efforts to provide accurate information, errors may have crept in. Please let us Continue reading QIDP Drug Update – Part 1: An Updated Who Is Who
Why are there so few boron-containing drugs on the market? The cancer drug bortezumib (Velcade®) may be the only better-known drug on the market with a boron atom in its structure.[1] Among antibiotics, there is Kerydin™ (tavaborole), an approved topical Continue reading Not So Boring: Boron-Containing Antibiotics Create a Stir